Etoricoxib: Analgesic drug, antiarthritic, cyclooxygenase-2 inhibitor

Drugs of the Future

Volumn 26, Issue 4, 2001, Pages 346-353

  Sorbera, L A ^a   Castaner R M ^a   Silvestre, J ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; ETORICOXIB; MELOXICAM; NIMESULIDE; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; NONHUMAN; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RAT; TOOTH PAIN;

EID: 0034963757     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.04.616043     Document Type: Article

References (42)

1. 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitors
2. A practical synthesis of a COX-2-specific inhibitor
3. Annulation of ketones with vinamidinium hexafluorophosphate salts: An efficient preparation of trisubstituted pyridines
4. An efficient preparation of vinamidinium hexafluorophosphate salts
5. Non-steroidal anti-inflammatory drugs and ulcers: Facts and figures multiply but do they add up?
6. Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs
7. COX-2 inhibitors
8. The cyclooxygenase isoforms: Structural insights into the conversion of arachidonic acid to prostaglandins
9. Celecoxib
10. Rofecoxib
11. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
12. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group
13. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
14. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
15. Valdecoxib and parecoxib sodium
16. Discovery of MK-0663, a highly selective inhibitor of cyclooxygenase-2
17. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2
18. Biochemical activity, safety and pharmacokinetics after multiple doses of MK-0663, a COX-2 specific inhibitor, in healthy volunteers
19. Lack of effect of antacids on single-dose pharmacokinetics of MK-0663
20. MK-0663 (a COX-2 inhibitor) did not affect prednisolone/prednisone plasma levels in healthy volunteers
21. MK-0663: A highly selective inhibitor of COX-2 in humans
22. The effect of the COX-2 inhibitor MK-0663 in treatment of acute pain using the dental pain model
23. Efficacy of etoricoxib, naproxen sodium, and acetaminophen/codeine in acute dental pain
24. Treatment with MK-663, a specific COX-2 inhibitor, resulted in clinical improvement in osteoarthiritis (OA) of the knee that was sustained over three months
25. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
26. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs
27. Predictability of the clinical potency of NSAIDs from the preclinical pharmacodynamics in rats
28. Comparison in rats of the anti-inflammatory and gastric irritant effects of etodolac with several clinically effective anti-inflammatory drugs
29. A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin
30. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2
31. 2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors
32. Rofecoxib [Vioox, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
33. Characterization of the analgesic and antiinflammatory activities of ketorolac and its enantiomers in the rat
34. Novel selective COX-2 inhibitors
35. Inhibition of prostaglandin biosynthesis by etodolac. I. Selective activities in arthritis
36. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer
37. Comparative anti-nociceptive, anti-inflammatory and toxicity profile of nimesulide vs nimesulide and piperine combination
38. High-throughput, semi-automated determination of a cyclooxygenase II inhibitor in human plasma and urine using solid-phase extraction in the 96-well format and high-performance liquid chromatography with post-column photochemical derivatization-fluorescence detection
39. MK-663, a specific COX-2 inhibitor for treatment of osteoarthritis (OA)